For effective clinical management of patients being treated with 223Ra, there is a need for
radiographic response biomarkers to minimize disease progression and to stratify patients …

Simple Summary This study was a retrospective investigation of a Japanese cohort of 205
metastatic castration-resistant prostate cancer (mCRPC) patients who received Ra-223 in 14 …

The aim of this study was to investigate the prognostic value of the quantitative assessment
of skeletal tumor burden on bone scintigraphy (Bone Scan Index [BSI]) in patients who have …

Background Radium‐223 improves survival and time to first symptomatic skeletal event in
symptomatic bone predominant metastatic castrate‐resistant prostate cancer (mCRPC). The …

Background Bone metastasis of prostate cancer is associated with pain and reduced overall
survival (OS). Radium‐223, which is expected to reduce bone pain and prolong OS, was …

Objective In mCRPC patients treated with 223 Ra, a major issue is the validation of reliable
prognostic and predictive biomarkers to maximize clinical benefit and minimize toxicities and …

Radiolabeled bisphosphonates such as 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic
acid (99mTc-DPD) typically show intense uptake in skeletal metastases from metastatic …

Background/Aim: Radium-223 dichloride (223RaCl2) represents a therapeutic option for
metastatic castration-resistant prostate cancer (mCRPC) patients dealing with symptomatic …

Background Having performed analytical validation studies, we are now assessing the
clinical utility of the upgraded automated Bone Scan Index (BSI) in metastatic castration …

Background Abiraterone acetate (AA) prolongs survival in metastatic castration-resistant
prostate cancer (mCRPC) patients. To measure treatment response accurately in bone …